31 Paid Clinical Research Studies in Bethesda, Maryland

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

This study will evaluate the safety and tolerability of an intramuscular injection of SAB-176 intended for use as a pre/post prophylactic for influenza. This is a Phase 1, randomi

📍 Naval Medical Research Command (NMRC) — Bethesda, Maryland

💵 This is a Phase 1, randomized, double-blind, placebo-controlled clinical trial in which a total of 28 subjects will rece

Chronic Pain Management In Primary Care Using Behavioral Health Consultants

The purpose of this randomized pragmatic trial is to assess the effect of monthly booster contacts on long-term Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP) pain o

📍 Uniformed Services University for the Health Sciences — Bethesda, Maryland

💵 Depending on how often the BHC can meet with the patient-participant to receive module care, participants could have a v

Patient-Centered Assessment of Symptoms and Outcomes

Background: The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different cau

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck

📍 Center for Cancer Research — Bethesda, Maryland

💵 A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Participants will receive the donated cells through their catheter.

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Background: Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastr

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Patients will receive pomalidomide once a day, days 1-21 of a 28-day cycle, at the various dose levels combined with lip

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Background: Neurofibromatosis type 1 (NF1) is a disorder that can cause plexiform neurofibromas (PNs). These are tumors that grow along nerves. Some PNs cause serious health probl

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Design: * This is a single site open label phase II study in which all subjects will receive selumetinib orally approxi

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 * Participants will receive PRGN-2009 and pembrolizumab prior to definitive treatment.

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in p

📍 National Cancer Institute — Bethesda, Maryland

💵 Participants will receive standard of care radiation therapy on weeks 9-11 and will be followed through 2 years post rad

Screening for Alpha Thalassemia in Healthy Volunteers

Background: Alpha thalassemia is a blood disorder. It is caused by genetic deletions. Part of the DNA is missing from a group of genes called alpha globin. Alpha thalassemias are

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Background: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 All subjects will receive post-transplant immunosuppression for graft-versus-host-disease (GVHD) prophylaxis for recipie

Evaluation of the Genetics of Bipolar Disorder

This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Background: * Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of reasons, including genetic predisposition to these cancers, e

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will com

📍 Walter Reed National Military Medical Center — Bethesda, Maryland

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Background: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are tr

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 If ongoing therapy for the underlying disease outside of the National Institutes of Health (NIH) is not in the best inte

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Background: Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells. The antibody Rituximab/Ruxience bi

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 * Patients will receive up to 4 cycles past documentation of CR without MRD, maximum 8.

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent ana

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

Background: \- Some nerve and muscle disorders that start early in life (before age 25), like some forms of muscular dystrophy, can run in families. However, the genetic causes of

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells. Th

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Participants will receive 2 chemotherapy drugs once a day for 3 days.

ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study

This study will examine genome sequencing in clinical research. Genome sequencing is a process in which researchers analyze (or sequence) part or all of the genome from a single pe

📍 Suburban Hospital — Bethesda, Maryland

💵 Each patient will receive a letter with results of the clinical laboratory values and evaluations.

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Background: \- Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a com

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Background: Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then ret

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Subjects will receive a novel non-myeloablative immunosuppressive conditioning regimen of cyclophosphamide and fludarabi

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Background: Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 * Participants will receive treatment in cycles consisting of 4 weeks.

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Background: Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels. As a result, affected pati

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Participants will receive abatacept 6 times, from just before they receive their donor cells until 6 months after.

Radium-223 in Biochemically Recurrent Prostate Cancer

Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically rec

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Objective: To determine statistically significant changes in immune cell populations compared to baseline in participan

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-o

📍 Mid-Atlantic Epilepsy and Sleep Center — Bethesda, Maryland

💵 As the daily doses of radiprodil will be individually titrated for every participant and all the participants will recei

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant ca

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Background: Bronchiolitis obliterans syndrome (BOS) is a complication people can experience after hematopoietic stem cell transplant. It usually affects people with chronic graft

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 * Patients will receive alvelestat (MPH966) using an intra-patient dose escalation schedule.

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Background: * Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies. One n

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 * Rituximab with bendamustine: Participants will receive rituximab on Days 1 and 15 of each cycle and bendamustine on Da

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. One approach to treating the

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 The vaccine is injected into a muscle; participants will receive their first dose of the vaccine on the same day as thei

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see i

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

💵 Participants will receive 8 cycles of DKd induction combination therapy.